Kindeva Drug Delivery announced that it will install a new MDI manufacturing line capable of filling either HFA-152a or HFO-1234ze, both of which have a lower global warming potential (GWP) than HFA 134a. The new line is expected to be in place by the end of 2022, and the company said that it plans to launch two MDIs formulated with the lower GWP propellants by 2025.
Kindeva CEO Aaron Mann commented, “We believe that once industry leaders like Kindeva enter this space and make transitioning products a reality, procurement and prescribing policy will rapidly move in favor of new greener pMDIs. Customers and health systems in the UK, EU and USA are becoming increasingly focused on decarbonization and the transition to Net Zero, and Kindeva is well placed to service their needs. There is simply no substitute for our experience in formulating and commercializing pMDIs and we are looking forward to making a major contribution to decarbonizing the global inhaler market.”
Mann continued, “We are therefore pleased that several key clients are already working with Kindeva on reformulating their existing products using low GWP propellants and are choosing to select the new propellants for future products, too. We will lead this transition to next-generation green propellants, just as we led the move from CFC to HFA propellants in the 1990s by launching the first CFC-free pMDI globally.”
Read the Kindeva Drug Delivery press release.
